Telesis Bio Management
Management criteria checks 2/4
Telesis Bio's CEO is Eric Esser, appointed in Jun 2022, has a tenure of 2.58 years. total yearly compensation is $683.56K, comprised of 62.2% salary and 37.8% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $73.18. The average tenure of the management team and the board of directors is 2.3 years and 0.5 years respectively.
Key information
Eric Esser
Chief executive officer
US$683.6k
Total compensation
| CEO salary percentage | 62.2% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.3yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$47m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$47m |
| Dec 31 2023 | US$684k | US$425k | -US$49m |
Compensation vs Market: Eric's total compensation ($USD683.56K) is about average for companies of similar size in the US market ($USD645.01K).
Compensation vs Earnings: Insufficient data to compare Eric's compensation with company performance.
CEO
Eric Esser (56 yo)
2.6yrs
Tenure
US$683,564
Compensation
Mr. Eric Esser serves as President of Telesis Bio, Inc. since May 1, 2023 and serves as its CEO & Director since April 18, 2024. He serves as Chief Operating Officer at Telesis Bio, Inc. (formerly known as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$683.56k | 0.015% $ 73.2 | |
| Chief Financial Officer | 1.4yrs | no data | no data | |
| Chief Technology Officer | 6.4yrs | US$1.33m | 0.29% $ 1.4k | |
| Vice President of Investor Relations | 2.1yrs | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Director of Investor Relations | no data | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: TBIO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$683.56k | 0.015% $ 73.2 | |
| Independent Director | 1.3yrs | US$254.30k | 0% $ 0 | |
| Independent Director | 3.7yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
0.5yrs
Average Tenure
56yo
Average Age
Experienced Board: TBIO's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 15:49 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Telesis Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brandon Couillard | Jefferies LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Douglas Schenkel | TD Cowen |